FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT.	OF CHA	NGESI	N RENEEL	CIAL OWN	VER 9

-0287
0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Biller Scott					<u>A</u> (	2. Issuer Name <b>and</b> Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC AGIO									all application	or (give title	g Person	10% Ow Other (s below)	ner
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET					03/	3. Date of Earliest Transaction (Month/Day/Year) 03/05/2018								Chief Scientific Officer					
(Street) CAMBRIDGE MA 02139			-   4. II -	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person										n					
(City)	(5		(Zip)																
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)			ection	ion 2A. Deemed Execution Date,		3.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a		d (A) or	5. Amou nd 5) Securitie Beneficia Owned F		nt of es ally Following	6. Owne Form: D (D) or In (I) (Instr	direct E	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	Amount (A) or (D) Pri			Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)
Common stock			03/05/	/2018	2018					3,000	A	\$9.0	05	56	5,059				
Common stock			03/05/	2018				<b>S</b> <sup>(2)</sup>		400	D	\$80.9	93 <sup>(3)</sup>	55	,659	D			
Common stock			03/05/	2018				<b>S</b> <sup>(2)</sup>		400	D	\$82.0	.04 <sup>(4)</sup> 55,		,259	D			
Common stock 03/05/2			/2018	018		S <sup>(2)</sup>		1,100	D	D \$83.21 <sup>(5)</sup>		54,159		D					
Common stock 03/05/2				/2018	.018		S <sup>(2)</sup>		1,100	D	\$84.	1(6)	<sup>(6)</sup> 53,059		D				
		T	able II								oosed of				wned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	te Executio		4. Transa	saction ce (Instr. E				xerci on Dat	sable and te	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amoun or Numbe of Shares	er					
Stock options (right to buy)	\$9.05	03/05/2018			M <sup>(1)</sup>			3,000	(7)		04/30/2023	Common stock	3,000		\$0.00	28,154		D	

## **Explanation of Responses:**

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$80.49 to \$81.35. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price
- 4. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$81.53 to \$82.36. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 5. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$82.65 to \$83.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 6. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$83.66 to \$84.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 7. This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

## Remarks:

/s/ William Cook, as Attorneyin-fact for Scott Biller

03/07/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.